Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Erdheim-Chester disease, drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
Kinase inhibitors are usually needed for life and relapse follows their withdrawal.
Nothing recorded yet.
Nothing recorded yet.
Background: Circulating tumour DNA (ctDNA). Also on OnCo: Treatment journeys · Survivorship planner.
Long-term cardiac, skin and secondary-cancer effects of indefinite BRAF and MEK inhibition are unknown.
Established fibrosis and neurological damage do not reverse.
Diagnosis is still delayed by years because the disease is unfamiliar.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 14 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Observation with periodic PET and organ screening.
Vemurafenib (approved 2017) or dabrafenib with trametinib; cobimetinib as an alternative; dose reduction to limit toxicity, treatment continued long term.
Cobimetinib (approved 2022 for histiocytic neoplasms); trametinib as an alternative MEK inhibitor.
Biopsy of an accessible lesion with BRAF V600E testing and broader sequencing; FDG-PET/CT, cardiac and brain MRI, endocrine assessment.